Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8271347 | 0.83 | MTNR1A (0.58) | L3MBTL1 | |
| SCHEMBL168006 | 0.83 | GAA (0.61) | GAALMNAPOLBHPGDALDH1A1 | |
| SCHEMBL14823336 | 0.81 | GAA (0.59) | GAALMNAPOLBHPGDALDH1A1 | |
| SCHEMBL29016424 | 0.80 | GAA (0.57) | GAALMNAPOLBHPGDALDH1A1 | |
| SCHEMBL28683590 | 0.79 | GAA (0.55) | GAALMNAPOLBHPGDALDH1A1 | |
| SCHEMBL10925171 | 0.78 | NPC1 (0.53) | GAALMNAPOLBALDH1A1NPC1 | |
| SCHEMBL3195736 | 0.77 | GAA (0.53) | GAALMNAPOLBHPGDALDH1A1 | |
| SCHEMBL12231008 | 0.76 | CYP3A4 (0.57) | GAALMNAPOLBALDH1A1NPC1 | |
| SCHEMBL23014132 | 0.75 | HDAC1 (0.58) | LMNAALDH1A1SMN1; SMN2HDAC1HDAC3 | |
| SCHEMBL4040134 | 0.74 | HPGD (0.51) | GAALMNAPOLBHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| US-8895781-B2 | Transition metal-catalyzed C—H amination using unactivated amines | GEORGETOWN UNIVERSITY (US) | 2014-11-25 | — | — | US | disclosed |
| US-20110213146-A1 | Transition Metal-Catalyzed C-H Amination Using Unactivated Amines | GEORGETOWN UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2010028159-A2 | TRANSITION METAL-CATALYZED C-H AMINATION USING UNACTIVATED AMINES | GEORGETOWN UNIVERSITY (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213146-A1 | Transition Metal-Catalyzed C-H Amination Using Unactivated Amines | AOC3, AOC2, MPO | GAA 2601/4885LMNA 3033/4885POLB 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.